Loading
A phase 2/3 trial of Fianlimab, Cemiplimab in non-small-cell lung cancer, run by Regeneron Pharmaceuticals, active and no longer recruiting.
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) is a phase 2/3 interventional study registered as NCT05785767 by Regeneron Pharmaceuticals, with 149 participants enrolled, started 2023-06-30 and due to reach its primary completion in 2027-09-28. Interventions recorded: fianlimab, cemiplimab, Placebo. Conditions listed: Advanced Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fianlimab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Shares Regeneron, PD-L1-high non-small-cell lung cancer without a driver mutation, Cemiplimab, Immune checkpoint inhibitors.
Shares Fianlimab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Shares Fianlimab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Shares Fianlimab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Shares Fianlimab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Shares Fianlimab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Shares Fianlimab, Regeneron, Cemiplimab, T-cell exhaustion and CAR-T persistence.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/